Enbrel Drug Interactions

Concurrent treatment with anakinra: Patients treated with Enbrel and anakinra were observed to have a higher rate of serious infection when compared with patients who were treated with Enbrel alone (historical data). In addition, in a double-blind placebo-controlled trial in patients receiving background methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious infections and neutropenia than patients treated with Enbrel alone (see Precautions).
Concurrent treatment with abatacept: In clinical studies, concurrent administration of abatacept and Enbrel therapy resulted in increased incidences of serious adverse events. This combination has not demonstrated increased clinical benefit; such use is not recommended (see Precautions).
Concurrent treatment with sulfasalazine: In a clinical study of patients who were receiving established doses of sulfasalazine, to which Enbrel was added, patients in the combination group experienced a statistically significant decrease in mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The clinical significance of this interaction is unknown.
Non-interactions: No interactions have been observed when Enbrel was administered with glucocorticoids, salicylates (except sulfasalazine), non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate in clinical trials with adult rheumatoid arthritis patients.
Methotrexate has no effect on the pharmacokinetics of etanercept.
No clinically significant pharmacokinetic drug-drug interactions were observed in studies with digoxin and warfarin.